300122 智飞生物
已收盘 02-27 15:00:00
资讯
新帖
简况
智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准
智通财经 · 02-26 15:46
智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准
智飞生物：截至2026年2月10日，公司普通股股东人数为126648
证券之星 · 02-14
智飞生物：截至2026年2月10日，公司普通股股东人数为126648
智飞生物：积极开展自主产品的国际注册、认证工作
证券之星 · 02-14
智飞生物：积极开展自主产品的国际注册、认证工作
智飞生物：截至2026年1月30日，公司普通股股东人数为128,281
证券之星 · 02-09
智飞生物：截至2026年1月30日，公司普通股股东人数为128,281
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准
智通财经网 · 02-09
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准
智飞生物最新公告：冻干水痘灭活疫苗获得临床试验批准通知书
证券之星 · 02-04
智飞生物最新公告：冻干水痘灭活疫苗获得临床试验批准通知书
智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准
智通财经 · 02-03
智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
智飞生物（300122）披露冻干乙型脑炎灭活疫苗临床试验申请获受理公告，1月30日股价下跌3.45%
证券之星 · 01-30
智飞生物（300122）披露冻干乙型脑炎灭活疫苗临床试验申请获受理公告，1月30日股价下跌3.45%
智飞生物：人二倍体狂犬病疫苗等处于上市审评阶段
证券之星 · 01-30
智飞生物：人二倍体狂犬病疫苗等处于上市审评阶段
智飞生物：贯彻“技术&市场”双轮驱动的发展战略
证券之星 · 01-29
智飞生物：贯彻“技术&市场”双轮驱动的发展战略
智飞生物：截至2026年1月20日，公司普通股股东人数为121,021
证券之星 · 01-28
智飞生物：截至2026年1月20日，公司普通股股东人数为121,021
智飞生物：目前该计划正常存续中
证券之星 · 01-28
智飞生物：目前该计划正常存续中
1月26日智飞生物涨14.87%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 01-26
1月26日智飞生物涨14.87%，招商国证生物医药指数(LOF)C基金重仓该股
股市必读：智飞生物（300122）1月23日董秘有最新回复
证券之星 · 01-26
股市必读：智飞生物（300122）1月23日董秘有最新回复
智飞生物：公司15价肺炎结合疫苗药品注册申请正在正常审评中
证券之星 · 01-23
智飞生物：公司15价肺炎结合疫苗药品注册申请正在正常审评中
智飞生物：公司持续优化经营策略，加速推进自研产品上市
证券之星 · 01-23
智飞生物：公司持续优化经营策略，加速推进自研产品上市
智飞生物2025年预亏超百亿，急筹102亿银团贷“过冬”
市场资讯 · 01-20
智飞生物2025年预亏超百亿，急筹102亿银团贷“过冬”
1月19日智飞生物跌7.19%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 01-19
1月19日智飞生物跌7.19%，招商国证生物医药指数(LOF)C基金重仓该股
股市必读：智飞生物（300122）1月16日董秘有最新回复
证券之星 · 01-19
股市必读：智飞生物（300122）1月16日董秘有最新回复
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":17.29,"timestamp":1772175819000,"preClose":17.23,"halted":0,"volume":10514274,"delay":0,"changeRate":0.0035,"floatShares":1414000000,"shares":2394000000,"eps":-0.5592,"marketStatus":"已收盘","change":0.06,"latestTime":"02-27 15:00:00","open":17.23,"high":17.33,"low":17.2,"amount":182000000,"amplitude":0.0075,"askPrice":17.29,"askSize":443,"bidPrice":17.28,"bidSize":553,"shortable":0,"etf":0,"ttmEps":-0.5592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":17.23,"symbolType":"stock","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":18.95,"lowLimit":15.51,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.41,"roa":"--","roe":"--","epsLYR":0.8427,"committee":0.14633,"marketValue":41389000000,"turnoverRate":0.0074,"status":0,"floatMarketCap":24453000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2614090899","title":"智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2614090899","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614090899?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:46","pubTimestamp":1772091974,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司近日收到全资子公司安徽智飞龙科马生物制药有限公司报告，由智飞龙科马自主研发的HK.3-JN.1新型冠状病毒mRNA疫苗获得国家药品监督管理局药物临床试验批准通知书，同意本品开展预防新型冠状病毒感染所致疾病的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300122","BK0239","LU2148510915.USD","BK0077","BK0188","LU2580892789.USD","LU1328615791.USD","159646","LU1064130708.USD","BK0196","BK0046","LU2580892862.HKD","LU1064131003.USD"],"gpt_icon":0},{"id":"2611164891","title":"智飞生物：截至2026年2月10日，公司普通股股东人数为126648","url":"https://stock-news.laohu8.com/highlight/detail?id=2611164891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611164891?lang=zh_cn&edition=full","pubTime":"2026-02-14 16:06","pubTimestamp":1771056367,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)02月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止至2026年2月10日收盘公司股东人数为多少，谢谢！智飞生物回复：您好，截至2026年2月10日，公司普通股股东人数为126648，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400011007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0046","LU2148510915.USD","LU2580892789.USD","BK0239","LU2580892862.HKD","LU1064130708.USD","BK0196","LU1328615791.USD","BK0077","300122","BK0188"],"gpt_icon":0},{"id":"2611116149","title":"智飞生物：积极开展自主产品的国际注册、认证工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2611116149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611116149?lang=zh_cn&edition=full","pubTime":"2026-02-14 16:03","pubTimestamp":1771056188,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)02月14日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在糖尿病GLP-1，减重药司美格鲁肽，癌症罕见病上的业务能力日益增强，将来是否具备与全球医药巨头相关业务的一争之力，从而更有利的拓展海外市场？智飞生物回复：您好，公司积极开展自主产品的国际注册、认证工作，针对未满足的临床需求提供创新产品，切实提升疫苗、治疗性产品的可及性、可担负性。公司海外的销售收入请持续关注公司的定期报告。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400010870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","LU1328615791.USD","LU2148510915.USD","BK0046","BK0196","LU1064131003.USD","LU2580892789.USD","300122","LU1064130708.USD","LU2580892862.HKD","BK0239"],"gpt_icon":0},{"id":"2610636399","title":"智飞生物：截至2026年1月30日，公司普通股股东人数为128,281","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610636399?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:57","pubTimestamp":1770631027,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好！截止1月30号，股东人数多少智飞生物回复：您好，截至2026年1月30日，公司普通股股东人数为128,281，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900023339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0188","BK0239","LU1064131003.USD","BK0196","LU2148510915.USD","LU2580892789.USD","LU1064130708.USD","LU2580892862.HKD","BK0046","BK0077","300122"],"gpt_icon":0},{"id":"2610633634","title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610633634","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610633634?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:12","pubTimestamp":1770628370,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的重组带状疱疹ZFA01佐剂疫苗获得国家药品监督管理局药物临床试验批准通知书，同意在40岁及以上人群中开展预防带状疱疹的临床试验。公司的重组带状疱疹ZFA01佐剂疫苗采用自主研制的新型佐剂，可同时激发细胞免疫与体液免疫反应，免疫应答更为全面，有望增强疫苗的保护效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064131003.USD","LU2580892862.HKD","LU1064130708.USD","LU2580892789.USD","LU2148510915.USD","LU1328615791.USD","BK0188","BK0077","300122","BK0196","BK0046","BK0239","159646"],"gpt_icon":0},{"id":"2608359903","title":"智飞生物最新公告：冻干水痘灭活疫苗获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608359903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608359903?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:41","pubTimestamp":1770194465,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司全资子公司智飞龙科马研发的冻干水痘灭活疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展预防水痘-带状疱疹病毒感染引起的水痘的临床试验。该疫苗采用创新灭活技术路线，生产用细胞株、毒株均为公司自主研发。目前国内有8款水痘减毒活疫苗获批上市使用，但暂无水痘灭活疫苗正式获批上市，市场前景广阔。该临床试验申请获得批准对公司近期业绩不会产生重大影响，但有利于公司夯实研发技术，加强在研管线储备。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400027715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0046","LU2580892862.HKD","BK0188","BK0239","LU1064131003.USD","LU2148510915.USD","BK0077","LU1064130708.USD","LU2580892789.USD","300122","BK0196"],"gpt_icon":0},{"id":"2608823578","title":"智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608823578","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608823578?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:05","pubTimestamp":1770105905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)研发的带状疱疹mRNA疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展用于预防带状疱疹的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","LU2580892862.HKD","LU1064130708.USD","LU2580892789.USD","LU2148510915.USD","LU1328615791.USD","BK0188","BK0077","300122","BK0196","BK0046","BK0239","159646"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["000661","BK0239","LU1969619763.USD","LU2148510915.USD","LU2580892789.USD","BK1161","688506","LU1223083913.SGD","LU2580892862.HKD","BK0046","LU1328615791.USD","LU1223082196.USD","BK1583","BK0077","LU1223082519.USD","BK0028","09995","BK0188","688331","BK0057","BK0075","LU1064130708.USD","LU2488822045.USD","BK1574","LU1064131003.USD","BK0196","BK4017","CDE","LU2328871848.SGD","300122"],"gpt_icon":0},{"id":"2607804924","title":"智飞生物（300122）披露冻干乙型脑炎灭活疫苗临床试验申请获受理公告，1月30日股价下跌3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607804924","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607804924?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:14","pubTimestamp":1769782462,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，智飞生物报收于17.37元，较前一交易日下跌3.45%，最新总市值为415.8亿元。该股当日开盘17.83元，最高17.93元，最低17.36元，成交额达5.3亿元，换手率为2.13%。智飞生物当日发布公告称，公司全资子公司安徽智飞龙科马生物制药有限公司研发的冻干乙型脑炎灭活疫苗临床试验申请获得国家药品监督管理局受理，受理号为CXSL2600147。该疫苗采用人二倍体细胞制备，具有较高的安全性。目前国内市场尚无同类技术生产的乙型脑炎灭活疫苗获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","LU1064131003.USD","BK0077","LU1064130708.USD","BK0196","LU2580892862.HKD","BK0239","300122","LU2148510915.USD","LU2580892789.USD","BK0188","LU1328615791.USD"],"gpt_icon":0},{"id":"2607097751","title":"智飞生物：人二倍体狂犬病疫苗等处于上市审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2607097751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607097751?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:30","pubTimestamp":1769761839,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物01月30日在投资者关系平台上答复投资者关心的问题。公司高度重视研发创新，形成智飞绿竹、智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，实现“预防&治疗”协同发展。目前人二倍体狂犬病疫苗、四价流脑结合疫苗、15价肺炎结合疫苗及利拉鲁肽注射液处于上市审评阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000027678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0046","LU1064130708.USD","300122","LU1064131003.USD","BK0077","LU1328615791.USD","LU2580892862.HKD","BK0188","LU2580892789.USD","159646","LU2148510915.USD"],"gpt_icon":0},{"id":"2607082777","title":"智飞生物：贯彻“技术&市场”双轮驱动的发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607082777?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:51","pubTimestamp":1769691091,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好请问公司未来的发展目标是什么？智飞生物回复：您好，公司贯彻“技术&市场”双轮驱动的发展战略，依托智飞绿竹、智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，实现“预防&治疗”协同发展。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900040873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","LU1328615791.USD","BK0046","BK0188","300122","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0196","LU2580892789.USD","BK0239","LU2580892862.HKD"],"gpt_icon":0},{"id":"2606034796","title":"智飞生物：截至2026年1月20日，公司普通股股东人数为121,021","url":"https://stock-news.laohu8.com/highlight/detail?id=2606034796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606034796?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:51","pubTimestamp":1769590276,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问公司到1月20日的股东人数，谢谢智飞生物回复：您好，截至2026年1月20日，公司普通股股东人数为121,021，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800028337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064131003.USD","BK0196","LU1328615791.USD","BK0077","BK0188","LU2148510915.USD","LU2580892789.USD","LU1064130708.USD","LU2580892862.HKD","300122","BK0046"],"gpt_icon":0},{"id":"2606960397","title":"智飞生物：目前该计划正常存续中","url":"https://stock-news.laohu8.com/highlight/detail?id=2606960397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606960397?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:51","pubTimestamp":1769590275,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好。据了解公司2022年的员工持股计划是进行了1:1的融资，截止到今天，公司的员工持股计划存不存在爆仓被动卖出的风险？智飞生物回复：您好，根据相关规定，公司员工持股计划由其管理委员会负责日常管理事宜，目前该计划正常存续中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800028336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU2580892862.HKD","BK0077","LU2580892789.USD","BK0188","BK0196","LU2148510915.USD","LU1064131003.USD","LU1328615791.USD","LU1064130708.USD","BK0046","BK0239"],"gpt_icon":0},{"id":"2606971562","title":"1月26日智飞生物涨14.87%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606971562","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606971562?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:50","pubTimestamp":1769413858,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日智飞生物涨14.87%，收盘报19.85元，换手率8.77%，成交量124.06万手，成交额23.64亿元。重仓智飞生物的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为14.39亿元，最新净值0.4131，较上一交易日上涨1.27%，近一年上涨15.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064130708.USD","BK0188","LU2580892862.HKD","LU2148510915.USD","399441","161726","LU2580892789.USD","BK0046","300122","LU1328615791.USD","LU1064131003.USD","BK0077","BK0196"],"gpt_icon":0},{"id":"2606680022","title":"股市必读：智飞生物（300122）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606680022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606680022?lang=zh_cn&edition=full","pubTime":"2026-01-26 01:28","pubTimestamp":1769362093,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，智飞生物报收于17.28元，上涨1.47%，换手率2.1%，成交量29.73万手，成交额5.12亿元。董秘最新回复投资者： 从2024年第四季度开始，公司开始出现亏损。2025年，公司从1季度到4季度，亏损逐步加大。董秘： 您好，公司15价肺炎结合疫苗药品注册申请正在正常审评中，审评审批进度请关注公示信息。董秘： 您好，截至2026年1月20日，公司普通股股东人数为121,021，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600000637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0046","LU1064131003.USD","LU2148510915.USD","BK0188","LU2580892789.USD","BK0239","BK0077","LU2580892862.HKD","LU1064130708.USD","BK0196","300122"],"gpt_icon":0},{"id":"2605475115","title":"智飞生物：公司15价肺炎结合疫苗药品注册申请正在正常审评中","url":"https://stock-news.laohu8.com/highlight/detail?id=2605475115","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605475115?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:48","pubTimestamp":1769161686,"startTime":"0","endTime":"0","summary":"投资者提问：我关注到贵公司旗下的全资子公司北京智飞绿竹自主研发的15价肺炎球菌结合疫苗已于去年6月申请生产注册并获得受理。智飞生物回复：您好，公司15价肺炎结合疫苗药品注册申请正在正常审评中，审评审批进度请关注公示信息。公司15价肺炎球菌结合疫苗涵盖了亚洲地区检出率最高的15种血清型，也符合国内的优势血清型分布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300029803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","LU1064131003.USD","BK0196","LU1328615791.USD","BK0077","BK0188","LU2148510915.USD","LU2580892789.USD","LU1064130708.USD","LU2580892862.HKD","300122","BK0046"],"gpt_icon":0},{"id":"2605473413","title":"智飞生物：公司持续优化经营策略，加速推进自研产品上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2605473413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605473413?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:27","pubTimestamp":1769160430,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)01月23日在投资者关系平台上答复投资者关心的问题。投资者提问：希望公司如实回答投资者：今年4月份年报过后，公司是否还会继续生产经营？智飞生物回复：您好，公司持续优化经营策略，加速推进自研产品上市，强化市场宣传推广，控制相关风险，促进公司可持续发展，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300028578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0046","LU2580892789.USD","BK0239","LU1328615791.USD","BK0188","300122","BK0196","BK0077","LU1064131003.USD","LU2580892862.HKD"],"gpt_icon":0},{"id":"2604728193","title":"智飞生物2025年预亏超百亿，急筹102亿银团贷“过冬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2604728193","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604728193?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:23","pubTimestamp":1768897380,"startTime":"0","endTime":"0","summary":" 曾凭借代理默沙东HPV疫苗实现营收与利润爆发式增长的智飞生物，正面临上市以来最严峻的经营危机，其2025年预计归母净利润亏损超百亿元，这也是上市首份年报亏损。 应收账款高企、短期偿债压力加剧背景下，智飞生物拟申请102亿元银团贷款补充资金，动用公司及大股东家族核心资产提供担保融资“过冬”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-01-20/doc-inhhxznv8938185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064131003.USD","BK0046","LU2148510915.USD","LU2580892789.USD","BK0239","LU2580892862.HKD","LU1064130708.USD","BK0196","LU1328615791.USD","BK0077","300122","BK0188"],"gpt_icon":0},{"id":"2604185464","title":"1月19日智飞生物跌7.19%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604185464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604185464?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:41","pubTimestamp":1768808495,"startTime":"0","endTime":"0","summary":"证券之星消息，1月19日智飞生物跌7.19%创60日新低，收盘报17.56元，换手率4.37%，成交量61.86万手，成交额11.02亿元。重仓智飞生物的前十大公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4203，较上一交易日下跌0.97%，近一年上涨17.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900014545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","BK0196","LU2580892789.USD","BK0046","BK0239","LU2148510915.USD","LU2580892862.HKD","BK0077","161726","LU1064131003.USD","300122","LU1328615791.USD","LU1064130708.USD","BK0188"],"gpt_icon":0},{"id":"2604979422","title":"股市必读：智飞生物（300122）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604979422","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604979422?lang=zh_cn&edition=full","pubTime":"2026-01-19 00:59","pubTimestamp":1768755547,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，智飞生物报收于18.92元，下跌2.57%，换手率2.21%，成交量31.3万手，成交额5.97亿元。投资者： 请问截至2026年1月10日，公司股东数是多少？董秘： 您好，截至2026年1月9日，公司普通股股东人数为122,938，谢谢！公司全资子公司智飞龙科马研发的带状疱疹mRNA疫苗已经获得国家药品监督管理局药物临床试验申请受理通知书。当日关注点来自“交易信息汇总”：1月16日主力资金净流出7320.69万元，显示主力短期减持动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900000341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","LU1328615791.USD","300122","LU1064131003.USD","LU2580892789.USD","BK0196","LU2148510915.USD","BK0077","LU1064130708.USD","BK0188","LU2580892862.HKD","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772176368119,"stockEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":-0.0756},{"period":"3month","weight":-0.162},{"period":"6month","weight":-0.2346},{"period":"1year","weight":-0.3436},{"period":"ytd","weight":-0.0869}],"compareEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.2267},{"period":"ytd","weight":0.0448}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"126648人(较上一季度减少1.27%)","perCapita":"11167股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}